Cytosorbents (CTSO) 2022 Annual Shareholders Meeting - Slideshow

Financial Performance & Strategy - CytoSorbents achieved a 5-year Compound Annual Growth Rate (CAGR) of 37% with 80% product gross margins in 2021[12] - The company anticipates funding operating needs and capital expenditures with existing cash, projecting to end the year with approximately $30 million in cash[20] - CytoSorbents has financial flexibility with a $15 million loan commitment from Bridge Bank if needed[20] - The company aims to become a top-tier international medical device company with FDA and EU approval, strong US and OUS sales growth, excellent product gross margins, profitability, and positive cash flow[15] Product Development & Market Expansion - CytoSorb is presented as a technology that removes a broad range of toxins that dialysis does not remove well, functioning like the liver with some kidney function, targeting large and fat-soluble molecules[9] - The company is focused on executing the STAR-T and STAR-D trials to gain U S market access for DrugSorb-ATR[13] - CytoSorbents has expanded its manufacturing capacity, increasing potential sales from $80 million to a range of $350 million-$450 million[12] - Over 170,000 treatments have been conducted with CytoSorb[22] Partnerships & Growth Opportunities - CytoSorbents has partnered with Nikkiso Medical, a leading manufacturer of dialysis machines, to supply PureADJUST machines and accessories, with a 14-country reseller agreement in place[31] - The partnership with Fresenius Medical Care includes a hemoperfusion reseller program for 14 countries[29] Clinical Programs - The company has 7 company-sponsored trials including STAR-T, STAR-D and PROCYSS, and 37 investigator-initiated studies[42]